menu

The NASH Epidemic: Highlights from the AMCP 2023 Symposium

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

The NASH Epidemic: Highlights from the AMCP 2023 Symposium

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Nonalcoholic steatohepatitis (NASH) is an epidemic with enormous health and economic implications. Join us for our chairman’s perspective on best practices to identify, screen, and refer patients. Dr. Mazen Noureddin also examines some of the emerging therapeutics that may change your approach to NASH.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Host:
    Mazen Noureddin, MD
    Medical Director
    Houston Research Institute
    Houston, TX  

    Advisory Board: 89bio, Altimmune, BI, BMS, Echosens, Gilead, GSK, Merck, Novo Nordisk, OWL, Pfizer, Roche Diagnostic, Siemens, Takeda, and Terns
    Principal Investigator for a Drug Study: Akero, Allergan, BMS, Conatus, Corcept, Enanta, Galectin, Genfit, Gilead, Madrigal, Novartis, Novo Nordisk, Shire, Terns, Viking, and Zydus
    Stockholder: Anaetos, ChronWell, CIMA, Rivus Pharma, Viking
    Editorial Board: Gastroenterology
    Associate Editor: Clinical Gastroenterology and Hepatology
    Federal funding: NIH/NIDDK      

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • John Maeglin has nothing to disclose.
    • Kate Nagele has nothing to disclose.
    • Jay Runyon has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Explain the benefit of early diagnosis and risk stratification for health outcomes in patients with nonalcoholic fatty liver disease (NAFLD)
    • Summarize the health and economic impact of nonalcoholic steatohepatitis (NASH)
    • Differentiate between treatment of NAFLD and NASH
    • Identify the FDA-defined efficacy endpoint of investigational treatments of NASH
  • Target Audience

    This activity is designed to meet the educational needs of managed care pharmacists and other managed care professionals, specialty and primary care physicians, physician assistants, nurse practitioners, and nurses.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until April 27, 2024. PAs should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for .25 contact hours/0.025 CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-23-017-H01-P. This learning activity is enduring-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Madrigal Pharmaceuticals. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Nonalcoholic steatohepatitis (NASH) is an epidemic with enormous health and economic implications. Join us for our chairman’s perspective on best practices to identify, screen, and refer patients. Dr. Mazen Noureddin also examines some of the emerging therapeutics that may change your approach to NASH.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Host:
    Mazen Noureddin, MD
    Medical Director
    Houston Research Institute
    Houston, TX  

    Advisory Board: 89bio, Altimmune, BI, BMS, Echosens, Gilead, GSK, Merck, Novo Nordisk, OWL, Pfizer, Roche Diagnostic, Siemens, Takeda, and Terns
    Principal Investigator for a Drug Study: Akero, Allergan, BMS, Conatus, Corcept, Enanta, Galectin, Genfit, Gilead, Madrigal, Novartis, Novo Nordisk, Shire, Terns, Viking, and Zydus
    Stockholder: Anaetos, ChronWell, CIMA, Rivus Pharma, Viking
    Editorial Board: Gastroenterology
    Associate Editor: Clinical Gastroenterology and Hepatology
    Federal funding: NIH/NIDDK      

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Libby Lurwick has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • John Maeglin has nothing to disclose.
    • Kate Nagele has nothing to disclose.
    • Jay Runyon has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Explain the benefit of early diagnosis and risk stratification for health outcomes in patients with nonalcoholic fatty liver disease (NAFLD)
    • Summarize the health and economic impact of nonalcoholic steatohepatitis (NASH)
    • Differentiate between treatment of NAFLD and NASH
    • Identify the FDA-defined efficacy endpoint of investigational treatments of NASH
  • Target Audience

    This activity is designed to meet the educational needs of managed care pharmacists and other managed care professionals, specialty and primary care physicians, physician assistants, nurse practitioners, and nurses.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. Approval is valid until April 27, 2024. PAs should claim only the credit commensurate with the extent of their participation in the activity. 

    Global Learning Collaborative (GLC) designates this activity for .25 contact hours/0.025 CEUs of pharmacy contact hours.

    The Universal Activity Number for this program is JA0006235-0000-23-017-H01-P. This learning activity is enduring-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net). 

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. 

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research. 

  • Commercial Support

    This activity is supported by an independent educational grant from Madrigal Pharmaceuticals. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule23 Feb 2024